1. Introduction {#sec1}
===============

*Amaryllidaceae* alkaloids have attracted the attention of medicinal^[@ref1]−[@ref4]^ and synthetic organic chemists^[@ref5]−[@ref8]^ for many decades in view of the diverse array of biological activities demonstrated. Examples include ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A) galanthamine (**1**) used clinically in the treatment of Alzheimer's disease,^[@ref9]^ the anticancer agent pancratistatin (**2**),^[@ref10]^ and the selective anticancer/antiviral agents *trans*-dihydronarciclasine (**3**)^[@ref11],[@ref12]^ and *trans*-dihydrolycoricidine (**4**).^[@ref13]^ The latter two alkaloids have recently been reported to exhibit potent activity against Zika virus,^[@ref12]^ herpes simplex virus type 1 (HSV-1), and varicella zoster virus.^[@ref13]^

![(A) Structure of representative *Amaryllidaceae* constituents galanthamine (**1**), pancratistatin (**2**), *trans*-dihydronarciclasine (**3**), and *trans*-dihydrolycoricidine (**4**) and (B) general quinazolidinone core structure (**5**), the novel *hybrid* heterocycle **6** and proposed retrosynthesis from an anthranilamide **7**, and pentose [l]{.smallcaps}-arabinose (**8**).](ao-2018-019873_0001){#fig1}

Despite the common structural motifs apparent in compounds **1--4**, these biological activities manifest through diverse mechanisms. Galanthamine is a potent inhibitor of acetylcholinesterase,^[@ref14]^ whereas pancratistatin selectively targets cancer cell mitochondria.^[@ref15]^ The antiviral profile is unusual with potent activity being reported against both DNA and RNA viruses,^[@ref11]−[@ref13]^ and accordingly several antiviral targets have been postulated.^[@ref16],[@ref17]^ Significant efforts have been made to elucidate the anticancer pharmacophore of pancratistatin. This work has revealed that ring-A substituents and the stereochemistry of ring-C substituents are crucial for activity,^[@ref18]−[@ref22]^ leading to the identification of analogues that are more potent than the natural products.^[@ref23],[@ref24]^ The ring-A 7-aza-analogue proved to be devoid of anticancer activity,^[@ref25]^ while the 10-aza-analogue was potent,^[@ref26]^ demonstrating the importance of the evaluation of aza analogues in revealing the subtle electronic requirements of the pharmacophore. The contribution of structural modifications on the antiviral activity is also critical^[@ref13]^ but much less established.^[@ref11]−[@ref13]^ Only a single report on the structure--activity relationship of ring-B modified lycoranes (dengue virus) has appeared.^[@ref27]^

The potent, selective antiviral activity of a series of quinazolinone derivatives ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}, **5**) was recently reported against HSV-1.^[@ref28],[@ref30]^ These compounds are accessible via a one-pot multicomponent coupling reaction of an amine, an aldehyde, and an anthranilamide derivative. High selectivity was observed for anti-HSV-1 activity in neuronal host cells for both compound **4** and the quinazolinones.^[@ref13],[@ref26]^ Given the synthetic challenges associated with the synthesis of fully functionalized alkaloids such as **3** and **4**,^[@ref5]−[@ref8],[@ref12],[@ref29]^ we have now explored a new *hybrid* quinazolinone--lycorane heterocyclic core shown as structure **6** ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). We envisioned that compounds such as **6** could be elaborated in an asymmetric fashion from an anthranilamide such as **7** and a chiral-pool pentose (such as **8**) in a few steps. In this communication, we report the success of this route and rapid synthesis of the compound of structural type **6**, including **21** which is the 10*b*-aza-analogue of the potent antiviral agent *trans*-dihydrolycoricidine (**4**), from [l]{.smallcaps}-arabinose in six steps (carried out in four chemical procedures) with a 23% overall yield.

2. Results and Discussion {#sec2}
=========================

Two initial attempts to fuse pentoses such as [d]{.smallcaps}-ribose and [l]{.smallcaps}-arabinose onto anthranilamide **7b** through N-alkylation of the protected 5-iodo analogues failed due to chemoselectivity incompatibilities, and we eventually settled on the process outlined in [Schemes [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}--[3](#sch3){ref-type="scheme"}. The C5 primary alcohol of [l]{.smallcaps}-arabinose, possessing the desired stereochemistry, was selectively protected as the TBS--ether **9** ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}), which, due to its hydrophilicity, was immediately engaged in the reductive amination with anthranilamide **7b** in the same reaction vessel affording intermediate **10**. After a short solvent partition sequence, the crude triol **10** was acylated to give **11**, which was isolated and purified over silica. The overall three-stage telescoped reaction sequence was highly efficient giving access to **11** with 64% overall yield (based on [l]{.smallcaps}-arabinose) over three steps, requiring only a single silica-gel chromatographic purification.

![[l]{.smallcaps}-Arabinose (**8**) Selectively Protected at C5 Alcohol as TBS-Ether Was Coupled to Anthranilamide (**7b**) via a Reductive Amination: (a) TBS-Cl, Pyridine; (b) NaCNBH~3~, MeOH; and (c) Ac~2~O, DIPEA, DCM](ao-2018-019873_0004){#sch1}

![Conversion of **11** via Deprotection, Oxidation, and Ring Closure to the Quinazolinone--Lycorane *Hybrids***15** and **16**: (d) HF·Py, THF; (e) IBX, DMSO, 60 °C; and (f) K~2~CO~3~, MeOH; Bottom: ORTEP Diagram of **14**](ao-2018-019873_0005){#sch2}

![Synthesis of **21** and **22** from [l]{.smallcaps}-Arabinose (**8**) and 3,4-Methylenedioxyanthranilamide (**7a**): (a) TBS-Cl, Pyridine; (b) NaCNBH~3~, MeOH; (c) Ac~2~O, DIPEA, DCM; (d) HF·Py, THF; (e) IBX, DMSO, 60 °C; and (f) K~2~CO~3~, MeOH](ao-2018-019873_0006){#sch3}

Removal of the TBS-protecting group in **11** employing tetrabutylammonium fluoride in THF gave the primary alcohol **12** contaminated with products of acetyl migration, attributed to these basic conditions. Conversely, the use of HF·pyridine complex in THF resulted in clean deprotection with no acyl transfer, and the desired primary alcohol **12** was isolated in high yield ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). The selective oxidation of the primary alcohol to the aldehyde proved more challenging than expected and a number of different conditions were investigated. An attempted Swern oxidation unexpectedly resulted in dehydration of the amide in **12** leading to the nitrile derivative, while an attempted oxidation under Parikh--Doering conditions failed completely, and no conversion of the starting material was observed. Reaction of **12** using Dess--Martin periodinane resulted in rapid decomposition of the starting material. Finally, oxidation with IBX in dimethyl sulfoxide (DMSO) at 60 °C was found to proceed selectively, the intermediate aldehyde immediately condensing as expected,^[@ref28]^ to give the desired fused-ring products **13** and **14** as a 1:2 mixture of separable diastereomers. Saponification of each of the separated diastereomers with K~2~CO~3~ in MeOH afforded the desired individual triols **15** and **16** completing the synthesis of these new *hybrid* model compounds. We also determined that, separately, **13** and **14** do not interconvert under the cyclization conditions, indicating them to be the products of a kinetically controlled intramolecular condensation.

A single crystal X-ray structural analysis of the major diastereomer **14** was conducted, confirming the overall course of the chemistry as anticipated and confirming the stereochemistry of the major diastereomer as shown in [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}. Interestingly, the 10*b*-aza heterocycle **14** was seen to adopt the *alternative* chair conformer as normally observed in the carbocyclic natural series. The C2- and C3-acetoxy and 4*a*-amino substituents of **14** adopt equatorial positions while the C4-acetoxy group projects axially. Diastereomer **14** crystallized as the thermodynamically more stable one of its chair conformers. A crystal structure of diastereomer **13** or deacetylated product **15** could not be obtained; however, the ^1^H NMR spectra of **15** is consistent (H4*a*, δ 4.59, d, *J* = 9.0 Hz) with the adoption of the natural phenanthridone-type chair conformer, having equatorial C4-hydroxyl and 4*a*-amino and diaxial C2, C3 alcohols. Thus, the diastereomeric pairs **13**/**14** or **15**/**16** adopt radically different three-dimensional projections of the crucial ring-C substituents with diastereomers **13** and **15** (and **19** and **21** vide infra) matching those of biologically active compounds such as **4**.

The synthetic route was now repeated with the 3,4-methylenedioxy-substituted anthranilamide **7a** ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}), essentially as before. The three-step telescoped intermediate **17** was isolated in a highly efficient 68% yield. Desilylation of **17** and IBX-mediated oxidation of **18** gave two ring-fused diastereomers **19** and **20** in a ratio of 3:4 (by mass). These diastereomers also proved readily separable over the silica gel, and each compound was independently saponified yielding the methylenedioxy-substituted quinazolidinone--lycorane *hybrids***21** and **22**. The chiral pool strategy thus allowed rapid, convergent fusion of [l]{.smallcaps}-arabinose onto the substituted anthranilamides giving access to **21**, the direct 10*b*-aza-analogue ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}, **6**) of *trans*-dihydrolycoricidine, and analogues **13**, **14**, **15**, **16**, **19**, **20**, **21**, and **22** (see [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}).

Preliminary anticancer investigations have been carried out on compound **4** and select 10*b*-aza-analogues. As the ring-A methylenedioxy substituent and free ring-C hydroxyl substituents are the known required features for anticancer activity,^[@ref11]^ the antiproliferative activity of compound **4** and the two hydroxyl derivatives **21** and **22** was investigated in four hematopoietic cancer cell lines. Compound **21** retained selective anticancer activity toward Karpas422 (9.72 μM), Toledo (18.9 μM), and K562 (13.23 μM) but was inactive toward MV4-11 cell lines. As expected, the synthetic compound **4** demonstrated potent broad-spectrum activity to Karpas422 (0.076 μM), Toledo (0.061 μM), and K562 (0.076 μM) and to the MV4-11 (0.073 μM) cell lines. The diastereomer **22** proved to be devoid of anticancer activity in all four cell lines investigated.

Preliminary anti-HSV-1 activity of select compounds has also been investigated with sharply defined results. As shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}, neurons infected with HSV-1 were cultured at 2 h post infection and were treated with test compounds. While the synthetic alkaloid **4** proved to be a potent inhibitor of HSV-1 replication as expected,^[@ref13]^ the *hybrid* 10*b*-aza derivatives **19**, **20**, **21**, and **22** demonstrated no inhibition of HSV-1.^[@ref28]^ The introduction of the 10*b*-aza nitrogen in **21** was not expected to change the ring-C conformation of the molecule significantly in comparison to **4**; however, the introduced dipole in **21** (vinylogous amide) was expected to affect the electronic properties. Given the sharp differences observed in the anti-HSV-1 activity of the compounds **4** and **21**, a detailed conformational analysis was conducted in an attempt to separate the electronic effects from the conformational/functional group attributes.

![Anti-HSV-1 activity of synthetic compounds **4** and **19**--**22** in neurons infected with HSV-1 expressing EGFP linked to the ICP90 promoter at MOI = 0.3; *Y*-axis depicts GFP+ cell percentage. Vehicle = uninfected and viral-infected untreated cells and ACV = acyclovir-positive control.](ao-2018-019873_0002){#fig2}

In addition to the X-ray analysis of diastereomer **14** (see 14, [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}), further evidence in support of the conformations was obtained through investigation of density functional theory (DFT) calculations on compounds **4**, **21,** and **22**, the calculated minima of which are depicted in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"} (see [Supporting Informatio](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01987/suppl_file/ao8b01987_si_001.pdf)n). Compounds **4** and **21** adopt the natural phenanthridone-type chair conformation in ring-C, whereas the aza-diastereomer **22** alone adopts the alternative conformer, identical to that observed in the X-ray structure of compound **14**. The antiviral and anticancer results thus correlate with the adoption of the biased phenanthridone-type chair conformation as a critical conformational requirement. The differences in anti-HSV-1 activity seen between compounds **4** (cyclohexane) and **21** (vinylogous amide) are remarkable, given the structural overlap seen. This work demonstrates that substitution of the 10b carbon with nitrogen is not tolerated for antiviral activity and that the natural phenanthridone-type ring-C conformation is required for potent anticancer activity and is crucial for antiviral activity. The structure--activity dichotomy between structures **4** and **21** is quite startling. Molecular electrostatic potential heat maps (see graphical abstract) show that **4** has an electropositive hole over ring-C, and aza-analogue **21** is less electropositive over this surface, highlighting a possible role of π-type secondary orbital interactions with the antiviral target.

![DFT-optimized molecular geometry (B3PW91/6-311+G(2d,p)) of compounds **4** (top left) and **21** (top right) illustrating identical ring-C phenanthridone-type conformations in contrast with diastereomer **22** (bottom).](ao-2018-019873_0003){#fig3}

Position 10*b* in these derivatives is the *only position* that may potentially affect the electrostatic potential of rings A, B, and C. The data show little effect on rings A and B, but a significant reduction in electron density in ring-C. The data draw attention to the different electronic distributions within the highest occupied molecular orbitals and lowest unoccupied molecular orbitals (see [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01987/suppl_file/ao8b01987_si_001.pdf) Figures S1--S3) of **4** and **21** as the only differences, suggesting increasing electron density toward position 10*b* as a method by which selective anticancer agents can be developed. The critical role of electronic properties (not conformational) of ring-C in analogue **4** for potent antiviral activity is unprecedented.

3. Conclusions {#sec3}
==============

In conclusion, we report a rapid six-step (four processes) convergent route to quinazolinone--*Amaryllidaceae* alkaloid hybrid molecules. The use of readily available chiral pool pentoses allows absolute control of three stereogenic centers and minimizes the number of stereoselective reactions required to produce the functionally dense core. Although there are several reports in the literature describing the antiviral and anticancer pharmacophore of *Amaryllidaceae* analogues, there are few reports of B/C-ring fusion-modified derivatives. The selective anticancer and antiviral activities reported here highlight the requirement of a correct ring-C (natural phenanthridone-type) chair conformation and reveal the unprecedented subtle role of electrostatic interactions required for antiviral activity and potent anticancer activity. Further studies exploring electronic modifications of fully functionalized analogues and their selective broad-spectrum antiviral and anticancer activities are ongoing.

4. Experimental Section {#sec4}
=======================

All reagents were obtained from MilliporeSigma and used as received unless otherwise specified. THF was distilled over sodium metal with a benzophenone indicator. Dichloromethane, methanol, and diisopropylethylamine were distilled over calcium hydride for use in reactions performed under anhydrous conditions. Reagent grade methanol, diethyl ether, dichloromethane, ethyl acetate, and hexane were used without further purification and for chromatography. Thin layer chromatography (TLC) was performed using aluminum sheets precoated with silica gel 60F~254~ (MACHEREY-NAGEL) and visualized using 254 nm UV light. ^1^H and ^13^C NMR spectra were recorded on a Bruker AV 600 spectrometer using CDCl~3~ or *d*~4~-MeOH as solvents. Chemical shifts (δ) are reported in ppm and coupling constants (*J*) are expressed in hertz.

4.1. (2*S*,3*R*,4*S*)-1-((*tert*-Butyldimethylsilyl)oxy)-5-((2-carbamoylphenyl)amino)pentane-2,3,4-triyl Triacetate (**11**) {#sec4.1}
----------------------------------------------------------------------------------------------------------------------------

A round-bottom flask was charged with [l]{.smallcaps}-arabinose (150 mg, 1.00 mmol, 1 equiv) and pyridine (1.20 mL, 15.0 mmol, 15 equiv). To this suspension, *t*-butyldimethylsilylchloride (163 mg, 1.05 mmol, 1.05 equiv) was added in portions. This reaction mixture was stirred at room temperature for 2 h and then concentrated to a total volume of 0.5 mL to afford protected sugar **9**. A solution of anthranilamide (130 mg, 0.95 mmol, 0.95 equiv) in dry methanol (1.0 mL) was added to the flask. After 10 min, NaCNBH~3~ (120 mg, 1.91 mmol, 1.9 equiv) was added. Upon completion of the reaction as determined by TLC (typically 5--10 min), water was added to quench the reaction mixture. This aqueous solution was extracted with dichloromethane (3 × 15 mL). The combined organic phase was dried over sodium sulphate and concentrated to dryness under reduced pressure to afford the crude product **10**, which contained an inseparable sugar impurity. In a round-bottom flask, crude **10** was dissolved in dry dichloromethane (3.3 mL) to which were added diisopropylethylamine (1.7 mL, 9.9 mmol, 10 equiv), acetic anhydride (566 μL, 6.0 mmol, 6 equiv), and *N*,*N*-dimethylaminopyridine (6.0 mg, 0.05 mmol, 0.05 equiv). This reaction mixture was stirred for 3 h at room temperature, and then quenched by the addition of water. This aqueous solution was extracted with dichloromethane (3 × 15 mL). The combined organic phase was dried over sodium sulphate and concentrated to dryness under reduced pressure. This material was then purified by gradient elution silica-gel chromatography (80:20 hexane/EtOAc → 30:70 hexane/EtOAc) to afford **11** as a yellow oil in a 64% isolated yield over the three-step sequence. ^1^H NMR (600 MHz, CDCl~3~): δ 7.44 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.36 (ddd, *J* = 8.6, 7.2, 1.6 Hz, 1H), 6.93 (d, *J* = 8.4 Hz, 1H), 6.70 (t, *J* = 7.5 Hz, 1H), 5.43 (dd, *J* = 8.4, 2.4 Hz, 1H), 5.38 (ddd, *J* = 8.1, 5.8, 2.4 Hz, 1H), 5.07 (ddd, *J* = 8.3, 5.0, 3.2 Hz, 1H), 3.73 (dd, *J* = 11.5, 3.2 Hz, 1H), 3.66 (dd, *J* = 11.5, 5.0 Hz, 1H), 3.39--3.31 (m, 2H), 2.13 (s, 3H), 2.09 (s, 3H), 2.01 (s, 3H), 0.85 (s, 9H), 0.01 (s, 3H), −0.00 (s, 3H); ^13^C NMR (151 MHz, CDCl~3~): δ 171.54, 170.75, 170.16, 170.02, 134.70, 133.81, 128.56, 116.96, 113.51, 108.00, 71.01, 69.66, 68.76, 61.82, 60.55, 44.35, 25.85, 21.10, 20.96, 20.89, 18.33, −5.42. ESI HRMS: calcd for C~24~H~38~N~2~O~8~Si \[M + H\]^+^, 511.2470; found, 511.2470; \[α\]~D~^20^ +14.4° (CHCl~3~, *c* 0.016).

4.2. (2*S*,3*R*,4*S*)-1-((2-Carbamoylphenyl)amino)-5-hydroxypentane-2,3,4-triyl Triacetate (**12**) {#sec4.2}
---------------------------------------------------------------------------------------------------

Compound **11** (107 mg, 0.20 mmol, 1.0 equiv) was dissolved in dry THF (3.2 mL) to which were added HF--pyridine (274 μL). This reaction mixture was stirred for 1 h at room temperature and then quenched by the addition of solid NaHCO~3~. After 15 min, water and dichloromethane were added to form an aqueous--organic partition. The aqueous was extracted exhaustively with dichloromethane and then the combined organic phases were dried with sodium sulphate and concentrated to dryness. This afforded **12** as a pale yellow oil in 92% yield, which was used immediately in the next transformation.

4.3. (2*S*,3*R*,4*S*,4*aR*)-6-Oxo-2,3,4,4*a*,5,6-hexahydro-1*H*-pyrido\[1,2-*a*\]quinazoline-2,3,4-triyl Triacetate (**13**) {#sec4.3}
----------------------------------------------------------------------------------------------------------------------------

2-Iodoxybenzoic acid (12 mg, 0.043 mmol, 1.2 equiv) was dissolved in reagent grade DMSO (100 μL) and heated to 60 °C for 30 min. A solution of compound **12** (15 mg, 0.036 mmol, 1.0 equiv) in DMSO (100 μL) was then added. This reaction mixture was stirred for 15 min at 60 °C and then purified directly by silica gel chromatography (100:0 Et~2~O/EtOAc → 90:10 Et~2~O/EtOAc) to afford **13** and **14** as a 1:2 mixture of diastereomers in 36% yield. **13** was obtained as a clear, colorless oil; ^1^H NMR (600 MHz, CDCl~3~): δ 7.95 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.40 (ddd, *J* = 8.7, 7.3, 1.7 Hz, 1H), 6.92 (td, *J* = 7.5, 0.9 Hz, 1H), 6.83 (s, 1H), 6.75 (d, *J* = 8.4 Hz, 1H), 5.49--5.45 (m, 1H), 5.29 (dd, *J* = 9.5, 3.0 Hz, 1H), 5.03 (dt, *J* = 4.1, 2.1 Hz, 1H), 4.95 (dd, *J* = 9.6, 1.9 Hz, 1H), 4.06 (dd, *J* = 14.5, 1.9 Hz, 1H), 3.26 (dd, *J* = 14.5, 2.1 Hz, 1H), 2.99 (s, 1H), 2.14 (s, 3H), 2.10 (s, 3H), 2.06 (s, 3H); ^13^C NMR (151 MHz, CDCl~3~): δ 170.10, 169.92, 169.21, 163.68, 147.93, 134.33, 129.18, 119.78, 116.41, 112.17, 69.67, 68.01, 67.09, 65.93, 44.03, 21.19, 20.94, 20.88. ESI HRMS: calcd for C~18~H~20~N~2~O~7~ \[M + H\]^+^, 377.1343; found, 377.1342; \[α\]~D~^20^ +69.9° (CHCl~3~, *c* 0.0029).

4.4. (2*S*,3*R*,4*S*,4*aS*)-6-Oxo-2,3,4,4*a*,5,6-hexahydro-1*H*-pyrido\[1,2-*a*\]quinazoline-2,3,4-triyl Triacetate (**14**) {#sec4.4}
----------------------------------------------------------------------------------------------------------------------------

Colorless solid. ^1^H NMR (600 MHz, CDCl~3~): δ 7.93 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.45 (ddd, *J* = 8.3, 7.4, 1.7 Hz, 1H), 6.95--6.87 (m, 2H), 6.31 (s, 1H), 5.46 (dd, *J* = 3.2, 1.7 Hz, 1H), 5.22 (td, *J* = 10.3, 4.9 Hz, 1H), 5.11 (dd, *J* = 10.2, 3.2 Hz, 1H), 4.92 (dd, *J* = 2.5, 1.7 Hz, 1H), 4.26 (dd, *J* = 13.4, 5.0 Hz, 1H), 2.76 (dd, *J* = 13.4, 10.5 Hz, 1H), 2.13 (s, 3H), 2.02 (s, 3H), 1.89 (s, 3H); ^13^C NMR (151 MHz, CDCl~3~): δ 170.47, 170.45, 170.10, 163.48, 147.10, 134.82, 128.70, 119.85, 116.42, 111.79, 70.90, 68.79, 65.64, 53.57, 46.01, 21.05, 20.79, 20.55. ESI HRMS: calcd for C~18~H~20~N~2~O~7~ \[M + H\]^+^, 377.1343; found, 377.1344; \[α\]~D~^20^ +77.2° (CHCl~3~, *c* 0.0067). A small sample suitable for X-ray diffraction was crystallized from hexanes/EtOAc (50:50) by slow evaporation in the refrigerator.

4.5. (2*S*,3*R*,4*S*,4*aR*)-2,3,4-Trihydroxy-1,2,3,4,4*a*,5-hexahydro-6*H*-pyrido\[1,2-*a*\]quinazolin-6-one (**15**) {#sec4.5}
---------------------------------------------------------------------------------------------------------------------

Compound **13** (3.5 mg, 0.01 mmol, 1.0 equiv) and K~2~CO~3~ (0.6 mg, 0.005 mmol, 0.5 equiv) were dissolved in a 3:1 mixture of methanol/water (100 μL). After 30 min, this mixture was purified directly by silica gel chromatography (100:0 DCM/MeOH → 80:20 DCM/MeOH) to afford **15** as a white, amorphous solid in 92% yield. ^1^H NMR (600 MHz, methanol-*d*~4~): δ 7.81 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.43 (ddd, *J* = 8.8, 7.2, 1.7 Hz, 1H), 6.98 (d, *J* = 8.4 Hz, 1H), 6.89--6.85 (m, 1H), 4.59 (d, *J* = 9.0 Hz, 1H), 4.02--3.98 (m, 2H), 3.95 (t, *J* = 3.5 Hz, 1H), 3.70 (dd, *J* = 13.0, 2.4 Hz, 1H), 3.13 (dd, *J* = 13.0, 2.3 Hz, 1H); ^13^C NMR (151 MHz, methanol-*d*~4~): δ 166.49, 151.39, 135.48, 129.12, 119.89, 117.76, 113.87, 71.61, 70.29, 69.77, 68.93, 46.82; \[α\]~D~^20^ +116.9° (MeOH, *c* 0.00092).

4.6. (2*S*,3*R*,4*S*,4*aS*)-2,3,4-Trihydroxy-1,2,3,4,4*a*,5-hexahydro-6*H*-pyrido\[1,2-*a*\]quinazolin-6-one (**16**) {#sec4.6}
---------------------------------------------------------------------------------------------------------------------

Compound **14** (8.0 mg, 0.02 mmol, 1.0 equiv) and K~2~CO~3~ (1.5 mg, 0.011 mmol, 0.5 equiv) were dissolved in a 3:1 mixture of methanol/water (200 μL). After 30 min, this mixture was purified directly by silica gel chromatography (100:0 DCM/MeOH → 80:20 DCM/MeOH) to afford **16** as a white, amorphous solid in 95% yield. ^1^H NMR (600 MHz, methanol-*d*~4~): δ 7.76 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.39 (ddd, *J* = 8.4, 7.3, 1.7 Hz, 1H), 6.90 (d, *J* = 8.3 Hz, 1H), 6.80 (td, *J* = 7.5, 0.9 Hz, 1H), 4.65 (d, *J* = 1.7 Hz, 1H), 3.97 (dd, *J* = 12.7, 5.2 Hz, 1H), 3.93--3.88 (m, 2H), 3.42 (dd, *J* = 9.4, 3.1 Hz, 1H), 2.53 (dd, *J* = 12.7, 10.6 Hz, 1H); ^13^C NMR (151 MHz, methanol-*d*~4~): δ 166.57, 150.30, 135.46, 128.99, 119.25, 117.31, 112.64, 75.47, 73.27, 71.57, 66.80, 49.85; \[α\]~D~^20^ −129.0° (MeOH, *c* 0.0038).

4.7. (2*S*,3*R*,4*S*)-1-((*tert*-Butyldimethylsilyl)oxy)-5-((6-carbamoylbenzo\[*d*\]\[1,3\]dioxol-5-yl)amino)pentane-2,3,4-triyl Triacetate (**17**) {#sec4.7}
----------------------------------------------------------------------------------------------------------------------------------------------------

A round-bottom flask was charged with [l]{.smallcaps}-arabinose (50 mg, 0.35 mmol, 1 equiv) and pyridine (400 μL, 15 mmol, 15 equiv). To this suspension, *t*-butyldimethylsilylchloride (54 mg, 0.36 mmol, 1.05 equiv) was added in portions. This reaction mixture was stirred at room temperature for 2 h, and then concentrated to a total volume of 0.5 mL. A solution of 3,4-methylenedioxyanthranilamide (60 mg, 0.33 mmol, 0.95 equiv) in dry methanol (320 μL) was added to the flask. After 10 min, NaCNBH~3~ (42 mg, 0.66 mmol, 1.9 equiv) was added. Upon completion of the reaction as determined by TLC (typically 2--5 min), water was added to quench the reaction mixture. This aqueous solution was extracted with dichloromethane (3 × 5 mL). The combined organic phase was dried over sodium sulphate and concentrated to dryness under reduced pressure. This mixture was dissolved in dry dichloromethane (1.0 mL) to which were added diisopropylethylamine (575 μL, 3.3 mmol, 10 equiv), acetic anhydride (187 μL, 1.98 mmol, 6 equiv), and *N*,*N*-dimethylaminopyridine (2.0 mg, 0.016 mmol, 0.05 equiv). This reaction mixture was stirred for 3 h at room temperature and then quenched by the addition of water. This aqueous solution was extracted with dichloromethane (3 × 15 mL). The combined organic phase was dried over sodium sulphate and concentrated to dryness under reduced pressure. This material was then purified by chromatography (80:20 hexane/EtOAc → 30:70 hexane/EtOAc) to afford **17** as a yellow oil in a 68% isolated yield over three steps. ^1^H NMR (600 MHz, CDCl~3~): δ 6.85 (s, 1H), 6.42 (s, 1H), 5.90 (s, 2H), 5.58 (s, 2H), 5.42 (dd, *J* = 8.4, 2.4 Hz, 1H), 5.33 (ddd, *J* = 7.7, 5.5, 2.4 Hz, 1H), 5.07 (ddd, *J* = 8.4, 5.0, 3.3 Hz, 1H), 3.73 (dd, *J* = 11.5, 3.2 Hz, 1H), 3.66 (dd, *J* = 11.4, 5.0 Hz, 1H), 3.33 (dd, *J* = 15.4, 5.9 Hz, 1H), 3.25 (dd, *J* = 14.5, 7.2 Hz, 1H), 2.13 (s, 3H), 2.08 (s, 3H), 2.02 (s, 3H), 0.86 (s, 9H), 0.02 (s, 3H), 0.01 (s, 3H); ^13^C NMR (151 MHz, CDCl~3~): δ 171.44, 170.59, 170.15, 169.99, 152.60, 147.91, 138.51, 107.12, 105.24, 101.43, 93.95, 71.08, 69.70, 68.89, 61.80, 44.26, 25.86, 21.13, 20.92, 20.89, 18.33, −5.41. ESI HRMS: calcd for C~25~H~38~N~2~O~10~Si \[M + H\]^+^, 555.2368; found, 555.2366; \[α\]~D~^20^ −8.7° (CHCl~3~, *c* 0.013).

4.8. (2*S*,3*R*,4*S*)-1-((6-Carbamoylbenzo\[*d*\]\[1,3\]dioxol-5-yl)amino)-5-hydroxypentane-2,3,4-triyl Triacetate (**18**) {#sec4.8}
---------------------------------------------------------------------------------------------------------------------------

Compound **17** (95 mg, 0.17 mmol, 1.0 equiv) was dissolved in dry THF (2.7 mL) to which were added HF--pyridine (233 μL). This reaction mixture was stirred for 20--30 min at room temperature and closely monitored by TLC to avoid the rearrangement of acetate-protecting groups. When the reaction was complete (typically 15--25 min), it was quenched by the addition of solid NaHCO~3~. After 15 min, water and dichloromethane were added to form an aqueous--organic partition. The aqueous was extracted exhaustively with dichloromethane, and then the combined organic phases were dried with sodium sulphate and concentrated to dryness. This afforded **18** as a pale yellow oil in 95% yield, which was used immediately in the next transformation.

4.9. (2*S*,3*R*,4*S*,4*aR*)-6-Oxo-2,3,4,4*a*,5,6-hexahydro-1*H*-\[1,3\]dioxolo\[4,5-*g*\]pyrido\[1,2-*a*\]quinazoline-2,3,4-triyl Triacetate (**19**) {#sec4.9}
-----------------------------------------------------------------------------------------------------------------------------------------------------

2-Iodoxybenzoic acid (54 mg, 0.20 mmol, 1.2 equiv) was dissolved in reagent grade DMSO (500 μL) and heated to 60 °C for 30 min. A solution of compound **18** (72 mg, 0.16 mmol, 1.0 equiv) in DMSO (200 μL) was then added. This reaction mixture was stirred for 15 min at 60 °C and then purified directly by silica gel chromatography (100:0 Et~2~O/EtOAc → 90:10 Et~2~O/EtOAc) to afford **19** and **20** as a 3:4 mixture of diastereomers in 45% yield. **19** was obtained as a clear, colorless oil; ^1^H NMR (600 MHz, CDCl~3~): δ 7.39 (s, 1H), 6.36 (s, 1H), 6.34 (s, 1H), 5.96 (d, *J* = 1.2 Hz, 1H), 5.45 (t, *J* = 3.6 Hz, 1H), 5.29 (dd, *J* = 9.2, 3.1 Hz, 1H), 5.06--5.04 (m, 1H), 4.84 (dd, *J* = 9.2, 1.5 Hz, 1H), 3.84 (dd, *J* = 14.2, 2.5 Hz, 1H), 3.23 (dd, *J* = 14.2, 2.4 Hz, 1H), 2.13 (s, 3H), 2.09 (s, 6H); ^13^C NMR (151 MHz, CDCl~3~): δ 170.07, 169.24, 163.56, 153.24, 145.57, 141.70, 131.05, 107.88, 101.87, 94.62, 69.38, 67.77, 66.94, 66.27, 44.97, 21.14, 20.92, 20.86. ESI HRMS: calcd for C~19~H~20~N~2~O~9~ \[M + H\]^+^, 420.1169; found, 420.1238; \[α\]~D~^20^ −13.4° (CHCl~3~, *c* 0.0031).

4.10. (2*S*,3*R*,4*S*,4*aS*)-6-Oxo-2,3,4,4*a*,5,6-hexahydro-1*H*-\[1,3\]dioxolo\[4,5-*g*\]pyrido\[1,2-*a*\]quinazoline-2,3,4-triyl Triacetate (**20**) {#sec4.10}
------------------------------------------------------------------------------------------------------------------------------------------------------

Clear, colorless oil. ^1^H NMR (600 MHz, CDCl~3~): δ 7.38 (s, 1H), 6.48 (s, 1H), 6.20 (s, 1H), 5.97 (d, *J* = 1.9 Hz, 2H), 5.46 (t, *J* = 2.7 Hz, 1H), 5.21 (td, *J* = 9.6, 4.7 Hz, 1H), 5.10 (dd, *J* = 9.6, 3.3 Hz, 1H), 4.83 (d, *J* = 2.2 Hz, 1H), 4.01 (dd, *J* = 13.0, 4.8 Hz, 1H), 2.74 (dd, *J* = 13.1, 9.6 Hz, 1H), 2.13 (s, 3H), 2.04 (s, 3H), 2.01 (s, 3H); ^13^C NMR (151 MHz, CDCl~3~): δ 170.48, 170.33, 170.05, 163.47, 153.25, 144.82, 141.96, 110.42, 107.65, 101.86, 95.15, 70.04, 69.74, 68.62, 66.06, 46.71, 21.04, 20.82, 20.74. ESI HRMS: calcd for C~19~H~20~N~2~O~9~ \[M + H\]^+^, 420.1169; found, 420.1247; \[α\]~D~^20^ +10.0° (CHCl~3~, *c* 0.094).

4.11. (2*S*,3*R*,4*S*,4*aR*)-2,3,4-Trihydroxy-1,2,3,4,4*a*,5-hexahydro-6*H*-\[1,3\]dioxolo\[4,5-*g*\]pyrido\[1,2-*a*\]quinazolin-6-one (**21**) {#sec4.11}
-----------------------------------------------------------------------------------------------------------------------------------------------

Compound **19** (4.7 mg, 0.011 mmol, 1.0 equiv) and K~2~CO~3~ (0.8 mg, 0.006 mmol, 0.5 equiv) were dissolved in 3:1 mixture of MeOH/water (130 μL). After 30 min, this mixture was purified directly by silica gel chromatography (100:0 DCM/MeOH → 80:20 DCM/MeOH) to afford **21** as a white, amorphous solid in 81% yield. ^1^H NMR (600 MHz, methanol-*d*~4~): δ 7.24 (s, 1H), 6.63 (s, 1H), 5.97 (s, 2H), 4.53 (d, *J* = 8.8 Hz, 1H), 4.03--3.99 (m, 2H), 3.94 (t, *J* = 3.6 Hz, 1H), 3.58 (dd, *J* = 12.9, 2.6 Hz, 1H), 3.13 (dd, *J* = 12.9, 2.3 Hz, 1H); ^13^C NMR (151 MHz, methanol-*d*~4~): δ 172.42, 161.63, 156.86, 141.98, 115.76, 110.87, 104.49, 79.50, 77.63, 77.21, 55.91, 49.53. ESI HRMS: calcd for C~13~H~14~N~2~O~6~ \[M + H\]^+^, 295.0925; found, 295.0917; \[α\]~D~^20^ +34.2° (MeOH, *c* 0.0023).

4.12. (2*S*,3*R*,4*S*,4*aS*)-2,3,4-Trihydroxy-1,2,3,4,4*a*,5-hexahydro-6*H*-\[1,3\]dioxolo\[4,5-*g*\]pyrido\[1,2-*a*\]quinazolin-6-one (**22**) {#sec4.12}
-----------------------------------------------------------------------------------------------------------------------------------------------

Compound **20** (12.0 mg, 0.029 mmol, 1.0 equiv) and K~2~CO~3~ (1.9 mg, 0.014 mmol, 0.5 equiv) were dissolved in a 3:1 mixture of methanol/water (250 μL). After 30 min, this mixture was purified directly by silica gel chromatography (100:0 DCM/MeOH → 80:20 DCM/MeOH) to afford **22** as a white, amorphous solid in 88% yield; ^1^H NMR (600 MHz, methanol-*d*~4~): δ 7.20 (s, 1H), 6.55 (s, 1H), 5.94 (d, *J* = 1.2 Hz, 2H), 4.55 (d, *J* = 1.9 Hz, 1H), 3.95--3.91 (m, 2H), 3.82 (dd, *J* = 12.4, 5.1 Hz, 1H), 3.43--3.41 (m, 1H), 2.49 (dd, *J* = 12.4, 10.4 Hz, 1H); ^13^C NMR (151 MHz, methanol-*d*~4~): δ 154.65, 148.18, 142.19, 129.60, 128.88, 107.69, 102.96, 95.32, 75.14, 72.39, 71.74, 67.08, 50.65. ESI HRMS: calcd for C~13~H~14~N~2~O~6~ \[M + H\]^+^, 295.0925; found, 295.0917; \[α\]~D~^20^ +60.2° (MeOH, *c* 0.0045).

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.8b01987](http://pubs.acs.org/doi/abs/10.1021/acsomega.8b01987).Computational methods for the DFT analysis and procedures for the synthesis of aza-alkaloid derivatives and copies of ^1^H and ^13^C NMR spectra ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01987/suppl_file/ao8b01987_si_001.pdf))

Supplementary Material
======================

###### 

ao8b01987_si_001.pdf

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

This work was supported by NSERC (to J.M.) and the Stanley Medical Research Institute (to J.M. and V.L.N.). C.E.B. is the recipient of a NSERC (Canada) postgraduate fellowship and T.K. of an NSERC undergraduate student research award.

The authors declare no competing financial interest.

Crystallographic data for compound **14** is deposited under CCDC file 1822440.

We thank Dr. Richard Marcellus at the Ontario Institute for Cancer Research in Toronto, ON for conducting the anticancer assays. Computing resources of SHARCnet \[Shared Hierarchical Academic Research Computing Network (of Ontario)\] were used in this study.
